Biogen flags sixth case of PML

Biogen Idec reported a sixth case of the potentially fatal brain disease progressive multifocal leukoencephalopathy, or PML, in a multiple sclerosis patient taking its drug Tysabri. According to Dow Jones, about 40,000 patients were using Tysabri at the end of the first quarter, and 24,900 of them have used the drug for a year or more. Report

Suggested Articles

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.